A comprehensive review of asthma mortality has found that many fatal and near-fatal asthma attacks are linked to preventable failures in patient care, highlighting persistent gaps in disease management despite the availability of effective treatments and evidence-based clinical guidelines. The paper, “Preventable Factors in Fatal and Near-Fatal Asthma: Lessons From the British Thoracic Society (BTS) and the National Review of Asthma Deaths (NRAD),” was published in the Cureus Journal of Medical Science.
The review examined lessons from the British Thoracic Society (BTS) asthma guidelines and findings from the United Kingdom’s National Review of Asthma Deaths (NRAD), which investigated the circumstances surrounding asthma-related deaths and identified recurring shortcomings in care. Researchers concluded that underuse of preventive medications, overreliance on rescue inhalers, inadequate follow-up care and poor recognition of high-risk patients remain major contributors to asthma mortality.
Although modern therapies have improved outcomes for many patients, researchers noted that the disease still causes hundreds of thousands of deaths annually, many of which could be prevented.
The NRAD investigation reviewed 195 confirmed asthma deaths across the United Kingdom and revealed troubling patterns. According to the report, 67% of asthma deaths involved potentially avoidable factors. Further findings showed that 45% of patients did not seek or receive medical attention during their final asthma attack, 39% had been prescribed more than 12 short-acting beta-agonist (SABA) inhalers in the year before death and 80% had no documented personalized asthma action plan.
Researchers identified several recurring risk factors associated with fatal and near-fatal asthma attacks. Poor adherence to inhaled corticosteroid (ICS) therapy, the cornerstone of long-term asthma control, was among the most common issues. Excessive reliance on SABA rescue inhalers was also strongly associated with poor asthma control and increased risk of severe exacerbations.
The review also highlighted failures within healthcare systems. Many patients who later died from asthma had not received routine asthma reviews, structured follow-up after severe attacks or comprehensive risk assessments. In several cases, opportunities to identify patients at elevated risk and intervene earlier were missed.
Patient education emerged as another critical factor. Investigators found that many individuals lacked written asthma action plans or adequate understanding of how to recognize worsening symptoms and seek timely medical care. Delayed response to deteriorating breathing problems was a common feature among fatal cases.
The review notes that BTS/SIGN guidelines and newer U.K. asthma recommendations provide a clear framework for reducing these risks. Key strategies include routine monitoring, personalized asthma action plans, regular assessment of inhaler technique, identification of high-risk patients and greater emphasis on controller medications that reduce airway inflammation.
Researchers also pointed to newer treatment approaches that move away from reliance on rescue inhalers alone. Current recommendations, they said, increasingly support anti-inflammatory reliever therapies that combine symptom relief with anti-inflammatory treatment, helping reduce severe exacerbations and hospitalizations.
Looking ahead, the review suggests that digital monitoring tools, smart inhalers, mobile health applications, biomarker-guided treatment and artificial intelligence-based risk prediction may further improve asthma management and help identify patients most at risk of severe outcomes.
